The 8 analysts offering 12-month price forecasts for Y-mAbs Therapeutics Inc have a median target of 9.00, with a high estimate of 20.00 and a low estimate of 4.00. The median estimate represents a +96.94% increase from the last price of 4.57.
The current consensus among 10 polled investment analysts is to Buy stock in Y-mAbs Therapeutics Inc. This rating has held steady since January, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.46
Reporting Date Feb 23
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.